Ione was a PhD student funded by an MRC Clinical Research Fellowship. She qualified in Medicine from Bristol Medical School and took time out from her neurology training in London to investigate the role of neuroinflammation in FTD. Her work focused on biomarkers such as TREM2, YKL-40 and chitotriosidase, and on microglial pathology in FTD. See her talk about her work here.
- 11th ICFTD (Sydney, November 2018): Cerebrospinal fluid microglia-derived biomarkers in familial frontotemporal dementia: results from the GENFI study
- 11th ICFTD (Sydney, November 2018): Microglial phenotypes differ according to gene mutation in familial frontotemporal dementia
- ABN Annual Meeting (Birmingham, May 2018): Cerebrospinal fluid sTREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup
- AAIC 2017 (London, July 2017): Pathological correlates of white matter hyperintensities on cadaveric MRI in progranulin-associated frontotemporal dementia
- AAIC 2017 (London, July 2017): Increased prevalence of non-thyroid autoimmune disease in patients with familial frontotemporal dementia associated with progranulin mutations
- 10th ICFTD (Munich, September 2016): Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
- 10th ICFTD (Munich, September 2016): Right temporal variant frontotemporal dementia and primary lateral sclerosis associated with dual C9orf72 and SQSTM1 mutations
- ARUK 2016 (Manchester, March 2016): Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
- J Neuroinflammation. 2020;17(1):234.
- Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. Woollacott IOC, Nicholas JM, Heller C, Foiani MS, Moore KM, Russell LL, Paterson RW, Keshavan A, Schott JM, Warren JD, Heslegrave A, Zetterberg H, Rohrer JD. Dement Geriatr Cogn Disord. 2020;49(1):56-76.
- Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. Woollacott IOC, Bocchetta M, Sudre CH, Ridha BH, Strand C, Courtney R, Ourselin S, Cardoso MJ, Warren JD, Rossor MN, Revesz T, Fox NC, Holton JL, Lashley T, Rohrer JD. Neurocase. 2018;24(3):166-174.
- Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Woollacott IOC, Nicholas JM, Heslegrave A, Heller C, Foiani MS, Dick KM, Russell LL, Paterson RW, Keshavan A, Fox NC, Warren JD, Schott JM, Zetterberg H, Rohrer JD. Alzheimers Res Ther. 2018;10(1):79.
- The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Woollacott IO, Rohrer JD. J Neurochem. 2016;138 Suppl 1:6-31.
